This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Takeda Pharmaceutical Company Ltd
Drug Names(s): TAK058, TAK-058
TAK-058 is a 5-HT3 receptor antagonist, under development by Takeda for the treatment of cognitive impairment associated with schizophrenia (CIAS).
Additional information available to subscribers only: